B&A Oncomedical

B&A Oncomedical is a French biotechnology company founded in 2020 by Professor Yehezkel Ben-Ari, specializing in the development of innovative therapies for resistant brain tumors and other diseases involving chloride homeostasis disruption. The company's research focuses on the interaction between tumor cells and their neuronal microenvironment, particularly the role of the NKCC1 transporter in tumor progression and invasion. Its lead program, COMBO, is a dual-therapy strategy combining the microtubule inhibitor mebendazole with the NKCC1 inhibitor bumetanide, currently in pre-clinical development for glioblastoma. B&A Oncomedical is also advancing its NKCCure platform, which includes over 120 proprietary next-generation NKCC1 inhibitors designed for superior potency and safety in oncology and neurological applications. The company leverages advanced ex vivo and in vitro models, including 3D tumoroids and electrophysiology, to validate its therapeutic candidates. B&A Oncomedical aims to provide concrete solutions for patients with aggressive cancers by restoring a balanced intracellular environment.